Trial Profile
OMPCa-Shanghai: An Open-label, Randomized Prospective Phase II Trial of Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) of the Primary Tumor in Oligometastatic Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Buserelin (Primary) ; Flutamide (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary) ; Triptorelin (Primary)
- Indications Carcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms OMPCa-Shanghai
- 06 Mar 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified July 2020).
- 13 Sep 2021 Primary endpoint has been met (Progression-Free Survival (radiographic progression-free survival) as per Results presented at the 116th Annual Meeting of the American Urological Association
- 13 Sep 2021 Results presented at the 116th Annual Meeting of the American Urological Association